425 related articles for article (PubMed ID: 1712765)
1. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease and toxic multinodular goiter.
Gedik O; Ozdemir T; Akalin S
Isr J Med Sci; 1991 Jul; 27(7):361-4. PubMed ID: 1712765
[TBL] [Abstract][Full Text] [Related]
2. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
Chen JJ; Ladenson PW
J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
[TBL] [Abstract][Full Text] [Related]
3. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
Khanna CM; Shankar LR; Jaggi CB; Bansal JK; Chugh P
J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
[TBL] [Abstract][Full Text] [Related]
4. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
5. Short and long term effects of radioiodine and antithyroid drugs on T4 binding proteins, free T4 and T3, during Graves' disease therapy.
Jaffiol C; Baldet L; Robin M; Papachristou C; Lapinski H; Mirouze J
Horm Metab Res; 1977 Jan; 9(1):73-81. PubMed ID: 66177
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter.
Nygaard B; Jarløv AE; Kristensen LO; Faber J
Horm Metab Res; 2000 Jul; 32(7):283-7. PubMed ID: 10965935
[TBL] [Abstract][Full Text] [Related]
7. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
8. [Clinical aspects, diagnosis and drug therapy of hyperthyroidism].
Bürgi U; Gerber H; Peter HJ
Schweiz Med Wochenschr; 1995 Aug; 125(31-32):1489-94. PubMed ID: 7545825
[TBL] [Abstract][Full Text] [Related]
9. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.
McIver B; Rae P; Beckett G; Wilkinson E; Gold A; Toft A
N Engl J Med; 1996 Jan; 334(4):220-4. PubMed ID: 8531998
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications.
Bayer MF; Kriss JP; McDougall IR
J Nucl Med; 1985 Nov; 26(11):1248-56. PubMed ID: 3840528
[TBL] [Abstract][Full Text] [Related]
11. Serum triiodothyronine to thyroxine ratio: a newly recognized predictor of the outcome of hyperthyroidism due to Graves' disease.
Takamatsu J; Kuma K; Mozai T
J Clin Endocrinol Metab; 1986 May; 62(5):980-3. PubMed ID: 3754263
[TBL] [Abstract][Full Text] [Related]
12. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
13. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
14. Enhanced thyroid iodine metabolism in patients with triiodothyronine-predominant Graves' disease.
Takamatsu J; Hosoya T; Naito N; Yoshimura H; Kohno Y; Tarutani O; Kuma K; Sakane S; Takeda K; Mozai T
J Clin Endocrinol Metab; 1988 Jan; 66(1):147-52. PubMed ID: 3335601
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity to lithium in treated Graves' disease: effects on serum T4, T3 and reverse T3.
Burman KD; Dimond RC; Earll JM; Wright FD; Wartofsky L
J Clin Endocrinol Metab; 1976 Sep; 43(3):606-13. PubMed ID: 989049
[TBL] [Abstract][Full Text] [Related]
16. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 1999 Nov; 84(11):4012-6. PubMed ID: 10566642
[TBL] [Abstract][Full Text] [Related]
17. Value of simultaneous T3, T4, and TSH measurements for management of graves' disease in children.
Golden MP; Kaplan SA; Lippe BM; Lee WN
Pediatrics; 1977 May; 59(5):762-7. PubMed ID: 577011
[TBL] [Abstract][Full Text] [Related]
18. Administration of additional inactive iodide during radioiodine therapy for Graves' disease: who might benefit?
Dietlein M; Moka D; Reinholz U; Schmidt M; Schomäcker K; Schicha H; Wellner U
Nuklearmedizin; 2007; 46(3):77-84. PubMed ID: 17549318
[TBL] [Abstract][Full Text] [Related]
19. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
Wallaschofski H; Kuwert T; Lohmann T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
[TBL] [Abstract][Full Text] [Related]
20. Serum thyroglobulin changes in patients with Graves' disease treated with long term antithyroid drug therapy.
Kawamura S; Kishino B; Tajima K; Mashita K; Tarui S
J Clin Endocrinol Metab; 1983 Mar; 56(3):507-12. PubMed ID: 6185525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]